Cardiovascular benefits Certain GLP-1 agonists (such as semaglutide and liraglutide) have been shown to reduce the risk of major cardiovascular events, particularly in people with existing heart disease or high cardiovascular risk
Nearly half of people who say they have been diagnosed with diabetes (45%) report currently using a GLP-1 medication, as do three in ten (29%) adults who say theyve been diagnosed with heart disease and about a quarter (23%) of those who report being diagnosed as overweight or obese in the past five years
Well break down practical ways to support GLP-1 through diet, movement, gut health, sleep, stress management and daily routines you can actually repeat
However, higher levels of intake of alpha-tocopherol (like achieved by taking supplements) are associated with decreased blood coagulation
Specific GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) have demonstrated cardiovascular benefits in people with type 2 diabetes who have established cardiovascular disease or high cardiovascular risk
10.1016/j.redox.2017.01.012 26 LammersL